FDA approved first therapy for children with debilitating and disfiguring rare disease
On Apr. 13, 2020 the FDA announced that given the increased demand for chloroquine phosphate and hydroxychloroquine sulfate, the FDA has published product-specific guidances to support generic drug development for these drugs.
Tags:
Source: U.S. Food and Drug Administration
Credit:
